Core Viewpoint - The company reported a strong performance in its interim results for the six months ending September 30, 2025, with significant growth in revenue and profit driven by robust sales of its core brands [1] Financial Performance - Revenue reached approximately HKD 430 million, representing a year-on-year increase of about 7.7% [1] - Profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were HKD 0.1412, with an interim dividend of HKD 0.0975 per ordinary share [1] Business Segments - The growth in performance was primarily attributed to strong sales in the branded pharmaceutical segment, particularly the He Ji Gong brand, and the traditional Chinese medicine segment, especially the Bao Ji Wan product [1] - The company emphasized effective brand management and successful market promotion as key factors in driving sales [1] - The traditional Chinese medicine formula granules business also showed stable performance, contributing consistently to the overall health business group [1]
健倍苗苗(02161)公布中期业绩 公司权益持有人应占溢利约为1.15亿港元 同比增加约20.0%